JCT  Vol.4 No.7 A , August 2013
R&D Landscape for Breast Cancer through Patent Documents
ABSTRACT

Cancer is a leading cause of death worldwide, and is estimated to be the cause of 13.1 million deaths in 2030. Breast cancer is the second cancer in the global mortality ranking, considering both sexes. Due to the burden of breast cancer worldwide, this paper aims to present an overview of the main R&D efforts focusing on breast cancer treatment. Patents were retrieved from the Derwent Innovations Index?, which has a specific code for pharmaceuticals related to breast cancer. A total of 423 patent documents filed in recent years were identified, of which 126 are exclusively for breast cancer, 169 for breast cancer and other cancers, and 128 are inventions related to the treatment of cancer and other diseases. The patent documents were classified into two large groups, the first of which had a predominance of claims for antibodies, proteins and polypeptides for use in medication production, while the second focuses on gene therapy, nucleotides and RNA. The country with the majority of priority patent applications was found to be the United States, followed by China and Japan.


Cite this paper
A. Antunes, I. Fierro, R. Guerrante, P. Santos and F. Mendes, "R&D Landscape for Breast Cancer through Patent Documents," Journal of Cancer Therapy, Vol. 4 No. 7, 2013, pp. 56-64. doi: 10.4236/jct.2013.47A009.
References
[1]   C. L. Canongia, “Model of Strategic Prospection: Synergies between Competitive Intelligence (CI), Knowledge Management (KM) and Foresight (F). A Case Study of the Use of Biotechnology in Drugs for the Treatment of Breast Cancer,” Ph.D. Dissertation, Federal University of Rio de Janeiro, Rio de Janeiro, 2004.

[2]   Organization for Economic Co-Operation and Development, “Frascati Manual: Proposed Standard Practice for Surveys on Research and Experimental Development, The Measurement of Scientific and Technological Activities,” OECD Publishing, Paris, 2002.

[3]   A. L. Porter and N. C. Newman, “Patent Profiling for Competitive Advantage—Deducing Who Is Doing What, Where, and When,” In: H. F. Moed, et al., Eds., Handbook of Quantitative Science and Technology Research, Springer, The Netherlands, 2004, pp. 587-612.

[4]   World Health Organization, International Agency of Research on Cancer, “GLOBOCAN,” 2008. http://globocan.iarc.fr/factsheets/populations/factsheet.asp?uno=900

[5]   Instituto Nacional de Cancer (INCA), “Tipos de Cancer,” 2013. http://www.inca.gov.br/ wps/wcm/connect/tiposdecancer/ site/home/mama

[6]   World Health Organization, International Agency of Research on Cancer, “GLOBOCAN 2008, IARC,” 2010. http://www.who.int/mediacentre/factsheets/fs297/en

[7]   National Cancer Institute, “General Information about Breast Cancer,” 2013. http://www.cancer. gov/cancertopics/pdq/treat ment/breast/Patient/page1

[8]   World Health Organization, “Genomics and World Health. Report of the Advisory Committee on Health Research,” 2002. http://www.who.int/en

[9]   Y. Kun and P. Tan, “Materials and Methods Relating to Breast Cancer Classification,” US Patent No. 2008193-938, 2008.

[10]   Y. Wang, J. X. Yu, Y. Jiang and F. Yang, “Laser Microdissection and Microarray Analysis of Breast Tumors Reveal Estrogen Receptor Related Genes and Pathways,” US Patent No. 2008305959, 2008.

[11]   H. Y. Chang and R. A. Gupta, “Linc RNAs in Cancer Diagnosis and Treatment,” US Patent No. 2012004278, 2012.

[12]   Y. Nakamura, T. Katagiri and S. Nakatsuru, “Method of Diagnosing Breast Cancer,” US Patent No. 2012010090, 2012.

[13]   R. M. Crooke and M. J. Graham, “Effects of Apolipoprotein B Inhibition on Gene Expression Profiles,” US Patent No. 2010331390, 2010.

[14]   Y. Paterson, P. Maciag, M. Seavey and S. Ferrone, “Compositions Comprising HMW-MAA and Fragments Thereof, and Methods of Use Thereof,” US Patent No. 200920-2587, 2009.

[15]   J. M. Cedarbaum, “Method of Administering and Using VEGF Inhibitors for the Treatment of Human Cancer,” US Patent No. 2008214465, 2008.

[16]   X. Cui, “FOXC1 Antibodies and Methods of Their Use,” US Patent No. 2012201752, 2012.

[17]   W. B. Kinlaw, “Prognosis and Treatment of Breast Cancer,” US Patent No. 2009232818, 2009.

[18]   C. Esslinger, S. Kuenzle, I. Abela, A. Zippelius, D. Jaeger, A. Knuth, R. Nitsch, H. Moch and N. Goebels, “Monoclonal Human Tumor-Specific Antibody,” US Patent No. 2010330075, 2010.

[19]   S. Chen and B. Zhu, “Nano-Scale Artificial Oil Body for Targeted Drug Delivery System Detection and Treatment,” Chinese Patent No. 102743327, 2012.

[20]   S. Y. Sun, “FK Gene, Coding Protein and Application Thereof,” Chinese Patent No. 101058604, 2007.

[21]   S. Y. Sun, “Breast Cancer Relevant P69 Gene, Coding Protein and Application Thereof,” Chinese Patent No. 10105-8808, 2007.

[22]   R. Niu, L. Zhang, D. Wang, Y. Shi, X. Wei, Y. Yang, J. Huang, Y. Niu, B. Sun and X. Hao, “Human Breast Cancer Resisting Recombination Immunotoxin M4G3/ ScFv-PE40,” Chinese Patent No. 101148475, 2008.

[23]   X. Yao, F. Wang, E. Song, H. Deng, D. Wang, J. Chen, Z. Dou and X. Ding, “Acceptor Protein, and Coding Gene and Application Thereof,” Chinese Patent No. 102475890, 2012.

[24]   S. Y. Yi, “Breast Cancer Related Gene DREE, Its Coded Protein and Uses,” Chinese Patent No. 1807455, 2006.

[25]   W. W. Jiang, “scFvC6.5-s Trail Fusion Gene and Protein, and Its Preparation,” Chinese Patent No. 1865445, 2006.

[26]   S. Wu and J. Gong, “Nucleic Acid Aptamer with High Specificity and High Affinity to Human Breast Carcinoma Tissue, Preparation Method and Application Thereof,” Chinese Patent No. 101148666, 2008.

[27]   S. Li, Y. Wang, J. Pan, Q. Zhao and H. Wang, “Humanized Breast Cancer Antigen and Antibody Thereof,” Chinese Patent No. 101962405, 2011.

[28]   Q. Wei, X. Cao, Y. Jun and Y. Lu, “Human Prolactin Receptor Antibody and Application Thereof,” Chinese Patent No. 102250244, 2011.

[29]   Y. Jiang, N. Zhang and Z. Xie, “Medicament for Curing Breast Carcinoma and Special Antisense Oligonucleotide Therefor,” Chinese Patent No. 101275134, 2008.

[30]   J. Luo, X. Wang, M. Liu, X. Tang and R. Jin, “GPR116 (G-Protein Coupled Receptor) Gene, Receptor Protein Coded by Same and Application of the GPR116 Gene,” Chinese Patent No. 102041259, 2011.

[31]   E. Song, J. Chen and X. Yao, “Application of PITPNM3 Gene in Preparing Medicine for Inhibiting Breast Cancer Invasion and Transfer,” Chinese Patent No. 102160895, 2011.

[32]   S. Yuan, Z. Shi, W. Han, Y. Zhang, R. Ling, N. Li and T. Wang, “Recombinant BCG Vaccine Based on Human MUC1 Repetitive Sequence and GM-CSF Fusion Expression,” Chinese Patent No. 101575607, 2009.

[33]   N. Guo, Z. Xie and M. Shi, “Heterogenetic Antigen-Fc Fusion Protein Capable of Inducing Antitumor Immunity of Organism and Application Thereof,” Chinese Patent No. 101638440, 2010.

[34]   Y. Liu and W. Zhang, “A Series of Recombinant AdenoAssociated Viral Vectors, Construction Methods and Uses Thereof,” Chinese Patent No. 102268458, 2011.

[35]   Z. X. Li, “Method for Coustructing shRNA Expression Carrier for Inhibiting N-Acetylglucosamine Transferase V and Its Use,” Chinese Patent No. 1936012, 2007.

[36]   W. T. Wang, “Construction of HER2/neu mRNA in Vitro Transcription Vector and Use Thereof,” Chinese Patent No. 1966684, 2007.

[37]   Y. Ge, X. Zhang, J. Zhang, L. Hou and M. Xue, “KDR siRNA and Application Thereof,” Chinese Patent No. 101215563, 2008.

[38]   J. Zhang, X. Ding, J. Zhou, S. Xiang, X. Hu and M. Han, “SiRNA for Inhibiting Human KCTD1 Gene Expression and Use Thereof in Pharmacy,” Chinese Patent No. 101481688, 2009.

[39]   M. Li, L. Jun, J. Cai, Y. Huang, J. Wu and J. Yuan, “Molecular Marker HSA-miR-374a of Breast Carcinoma and Application Thereof,” Chinese Patent No. 101633922, 2010.

[40]   J. Dong, L. Fu, D. Su, X. Wu and Z. Zhu, “Breast Cancer Related Gene C10RF64 and Application Thereof,” Chinese Patent No. 101701220, 2010.

[41]   T. Nagahata and M. Emi, “Material for Suppressing SEPT11 Gene Expression,” Japanese Patent No. 254830, 2006.

[42]   N. Goto, M. Murohashi, H. Yuya, T. Isagawa and M. Kuroda, “Test Method for Predicting Recurrence of Solid Cancer and Recurrence Prophylactic,” Japanese Patent No. 2010178650, 2010.

[43]   S. Watanabe, M. Ito, J. Imai, T. Otake, T. Fujita and Y. Sakai, “Method for Discriminating Subtype of Breast Cancer,” Japanese Patent No. 2012085554, 2012.

[44]   S. Watanabe, M. Ito, J. Imai, T. Otake, T. Fujita and Y. Sakai, “Method for Diagnosis of Breast Cancer,” Japanese Patent No. 2012085556, 2012.

[45]   T. Nagahata and M. Emi, “RA13 Gene Expression Inhibitor,” Japanese Patent No. 2005287456, 2005.

[46]   H. Nakatake and C. Nozaki, “Inhibitory Antibody against Malignant Tumor Cell Growth,” Japanese Patent No. 2005-206508, 2005.

[47]   Y. Nakamura, H. Yasuoka, M. Tsujimoto, R. Goto, Z. Totsuka, K. Momiyama, K. Kakudo and N. Takami, “Therapeutic Agent for Highly Malignant Breast Cancer,” Japanese Patent No. 2008110975, 2008.

[48]   Y. Sugimoto, S. Tsukahara and Y. Imai, “Anticancer AgentResistance Overcoming Agent,” Japanese Patent No. 2006-069910, 2006.

[49]   C. W. Kim and J. Y. Jang, “Method for Treating Breast Cancer by Decreasing the Expression of Adenine Nucleotide Translocator 2 mRNA,” Korean Patent No. 2012-0095263, 2012.

[50]   D. K. Lee and H. S. Kang, “Nucleic Acid Aptamer Capable of Specifically Binding to HER-2-Overexpressing Breast Cancer Cell or Tissue and Use Thereof,” Korean Patent No. 20110086433, 2011.

[51]   D. S. F. Young, H. P. Findlay, S. E. Hahn and L. M. Cechetto, “Cancerous Disease Modifying Antibodies,” US Patent No. 2009104115, 2009.

[52]   W. Yin, W. Xia, Y. Ma, C. Zhao, Y. Hong, J. Han and H. Chen, “Application Method for Medicament Based on NAD<+> and NADH,” Chinese Patent No. 102061285, 2011.

[53]   H. Q. Nguyen, F. Lin, X. Bi, H. J. Mcbride and S. S. Hu, “Anti-Oral Antigen Binding Proteins and Uses Thereof,” US Patent No. 2012231006, 2012.

[54]   J. Collard, O. K. Sherman, C. Coito and B. Leon, “Treatment of Sirtuin 1 (SIRT1) Related Disease by Inhibition of Natural Antisense Transcript to SIRT1,” Chinese Patent No. 102307997, 2012.

 
 
Top